Completed PHASE3 INTERVENTIONAL 2-arm NCT06343779

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema (RAPIDe-3)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults With Hereditary Angioedema

Sponsor: Pharvaris Netherlands B.V.

Conditions C1 Esterase Inhibitor Deficiency C1 Esterase Inhibitor [C1-INH] Deficiency C1 Esterase Inhibitor, Deficiency of C1 Inhibitor Deficiency Hereditary Angioedema Hereditary Angioedema - Type 1 Hereditary Angioedema - Type 2 Hereditary Angioedema - Type 3 Hereditary Angioedema Attack Hereditary Angioedema Type I Hereditary Angioedema Type II Hereditary Angioedema Type III Hereditary Angioedema Types I and II Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

Interventions Deucrictibant, Placebo

Updated 11 times since 2024 Last updated: Nov 20, 2025 Started: Feb 26, 2024 Primary completion: Oct 17, 2025 Completion: Oct 17, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates C1 Esterase Inhibitor Deficiency and C1 Esterase Inhibitor [C1-INH] Deficiency and is currently completed. Pharvaris Netherlands B.V. leads this study, which shows 11 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3

Status: Recruiting → Completed
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE3
May 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Feb 2025 — May 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE3

▶ Show 6 earlier versions

Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3

First recorded

Feb 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharvaris Netherlands B.V.

Data source: Pharvaris Netherlands B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Barcelona, Spain , Berlin, Germany , Birmingham, United States , Bogotá, Colombia , Boston, United States , Box Hill, Australia , Bristol, United Kingdom , Brno, Czechia and 59 more locations